# Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

> **NCT02581930** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 18 (actual)

## Conditions studied

- Metastatic Melanoma
- Recurrent Cutaneous Melanoma
- Stage IV Cutaneous Melanoma AJCC v6 and v7

## Interventions

- **DRUG:** Ibrutinib
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacogenomic Study
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT02581930
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-08-17
- **Primary completion:** 2018-02-10
- **Final completion:** 2027-03-04
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02581930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02581930, "Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02581930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*